By Billy Candra 
Mammograms, traditionally a cornerstone in breast cancer detection, are now poised to become a powerful dual-screening tool, revealing much more than malignant growths. A groundbreaking study, presented at the American College of Cardiology’s Annual Scientific Session (ACC.25), demonstrates how integrating artificial intelligence (AI) models can transform these routine screenings into comprehensive cardiovascular health assessments. The pivotal findings highlight the potential for mammography to quantify calcium buildup in the arteries within breast tissue, a critical and often overlooked indicator of cardiovascular disease (CVD) risk, thereby providing an unprecedented opportunity for early intervention in women.
The Overlooked Indicator: Breast Arterial Calcification
The U.S. Centers for Disease Control and Prevention (CDC) advocates for regular mammograms—an X-ray examination of the breast—for middle-aged and older women, typically every one to two years, to screen for breast cancer. Annually, approximately 40 million mammograms are performed across the United States, underscoring their widespread adoption as a vital preventative health measure. While breast artery calcifications (BAC), which appear as bright pixels on these X-ray images, are visible to radiologists, this information is not routinely quantified or reported to patients or their clinicians. This omission represents a significant missed opportunity, given the well-established link between vascular calcification and cardiovascular health.
Cardiovascular disease remains the leading cause of death globally and in the United States, tragically claiming more lives than all forms of cancer combined. For women, in particular, heart disease often presents atypically compared to men, leading to delayed diagnosis and treatment. Symptoms can be subtle, such as fatigue, shortness of breath, or discomfort in the jaw or back, rather than the classic crushing chest pain. This contributes to a lagging awareness among both the public and some healthcare providers, resulting in underdiagnosis and suboptimal management of cardiovascular conditions in women.
The presence of calcium deposits in blood vessel walls is a recognized sign of arterial damage, often associated with early-stage atherosclerosis—the hardening and narrowing of arteries due to plaque buildup—and aging. Prior research has consistently demonstrated that women exhibiting calcium buildup in their breast arteries face a significantly elevated risk of future cardiovascular events. Specifically, studies have indicated a 51% higher risk of heart disease and stroke in women with noticeable BAC, underscoring its clinical importance as a prognostic marker. Despite this clear correlation, the lack of standardized reporting mechanisms has meant that millions of women undergoing mammograms each year are unknowingly missing out on a critical piece of information about their heart health.
A New Era of Opportunistic Screening through AI
The new study bridges this critical gap by leveraging advanced AI image analysis. The research introduces a novel deep-learning AI model, meticulously trained to segment and quantify calcified vessels directly from mammogram images. This segmentation approach is a significant differentiator from previous AI models developed for analyzing breast artery calcifications, allowing for a more precise and nuanced assessment of calcification burden. By automatically analyzing BAC and translating these findings into a cardiovascular risk score, the AI tool offers a scalable solution for integrating cardiac risk assessment into routine breast cancer screening.
Dr. Theo Dapamede, MD, PhD, a postdoctoral fellow at Emory University in Atlanta and the study’s lead author, articulated the profound potential of this innovation: "We see an opportunity for women to get screened for cancer and also additionally get a cardiovascular screen from their mammograms." He further emphasized the clinical relevance of their findings: "Our study showed that breast arterial calcification is a good predictor for cardiovascular disease, especially in patients younger than age 60. If we are able to screen and identify these patients early, we can refer them to a cardiologist for further risk assessment." This concept of "opportunistic screening" capitalizes on an already established and widely utilized healthcare touchpoint, minimizing the need for additional appointments or specialized tests, thus enhancing patient convenience and potentially reducing healthcare costs.
The robustness of the AI model is further strengthened by its reliance on an exceptionally large and comprehensive dataset for both training and testing. Researchers utilized images and extensive electronic health records (EHR) data from over 56,000 patients who underwent mammograms at Emory Healthcare between 2013 and 2020. Crucially, this dataset included at least five years of follow-up EHR data for each patient, providing a rich longitudinal perspective necessary to validate the AI’s predictive capabilities for long-term cardiovascular outcomes. This collaboration between Emory Healthcare and Mayo Clinic underscores a synergistic approach to leveraging institutional data and expertise for innovative medical advancements.
Unpacking the Study’s Findings: Predictive Power and Age Stratification
The overall findings of the study unequivocally demonstrated the new AI model’s efficacy in characterizing patients’ cardiovascular risk. Based solely on mammogram images, the model accurately categorized risk into low, moderate, or severe levels. To assess its predictive power, researchers calculated the risk of major adverse cardiovascular events—defined as dying from any cause, suffering an acute heart attack, stroke, or heart failure—at two and five years post-mammogram.
The results revealed a clear and concerning trend: the rate of these serious cardiovascular events consistently increased with higher levels of breast arterial calcification. This correlation was particularly pronounced in two of the three age categories assessed: women younger than age 60 and those aged 60-80. Intriguingly, this pattern was not observed in women over age 80, suggesting that BAC may serve as a more potent early warning signal for heart disease risk in younger and middle-aged women, who stand to benefit most from early interventions and lifestyle modifications.
Specifically, the study highlighted stark differences in event-free survival rates. Women with the highest level of breast arterial calcification (above 40 mm²) had a significantly lower five-year rate of event-free survival compared to those with the lowest level (below 10 mm²). For instance, only 86.4% of those with the highest BAC survived for five years without a major cardiovascular event, in contrast to a robust 95.3% survival rate among those with the lowest levels of calcification. This translates to an approximately 2.8 times higher risk of death within five years for patients exhibiting severe breast arterial calcification compared to those with little to no BAC, a statistic that underscores the urgent need for such a screening tool.
Expert Perspectives and Interdisciplinary Collaboration
The potential integration of this AI tool into routine mammography holds profound implications for various stakeholders within the healthcare ecosystem.
Radiologists: For radiologists, this innovation represents a shift from solely focusing on breast pathology to a broader diagnostic role. While the AI automates the quantification, radiologists would be responsible for reviewing the AI-generated risk scores and potentially communicating these findings. This would necessitate new training protocols and integration into existing reporting workflows, potentially increasing their workload but significantly enhancing the value of their reports. Experts in radiology foresee a future where their specialty provides more holistic health insights, moving beyond organ-specific diagnostics.
Cardiologists: Cardiologists stand to benefit immensely from a steady stream of early referrals of at-risk women. This allows for proactive management, including comprehensive risk factor assessment, lifestyle counseling, and pharmacotherapy, well before the onset of overt symptoms or acute events. Dr. Dapamede’s vision of referring identified patients to a cardiologist for further risk assessment aligns perfectly with preventative cardiology principles. This could lead to a substantial reduction in the incidence and severity of cardiovascular events in women.
Public Health Officials: From a public health standpoint, this AI-enabled screening represents a significant leap forward in preventative medicine. Heart disease is a massive public health burden, and tools that can identify at-risk individuals early, especially within existing screening programs, are invaluable. It offers a scalable, cost-effective strategy to improve population health outcomes, reduce healthcare expenditures associated with late-stage disease management, and address health disparities, particularly among underserved populations where access to specialized cardiac screening might be limited.
Patient Advocacy Groups: Organizations focused on women’s health and cardiovascular disease would likely welcome this development as a means to empower women with more comprehensive health information. It could facilitate greater awareness of personal cardiovascular risk, encouraging proactive engagement in health management and fostering better dialogue with their healthcare providers.
The Road Ahead: Validation and Integration
Despite its promising results, the AI model developed by the Emory Healthcare and Mayo Clinic collaboration is not yet commercially available. The next critical steps involve rigorous external validation in diverse patient populations and healthcare settings to ensure its generalizability and robustness. Following successful validation, the tool will need to undergo the stringent approval process of the U.S. Food and Drug Administration (FDA). This regulatory pathway ensures the safety, efficacy, and clinical utility of new medical devices and software.
Integrating such an advanced AI tool into routine clinical practice presents its own set of challenges. These include ensuring seamless compatibility with existing mammography equipment and electronic health record systems, developing standardized reporting guidelines, and providing adequate training for radiologists and other healthcare professionals. Furthermore, ethical considerations surrounding AI in medicine, such as data privacy, algorithmic bias, and accountability, must be carefully addressed to foster trust and ensure equitable application of the technology. However, if these hurdles are successfully navigated, researchers are optimistic that the tool could be made commercially available, allowing healthcare systems worldwide to incorporate it into their routine mammogram processing and follow-up care protocols.
Broader Horizons: Beyond Cardiovascular Health
The innovative application of deep learning in this study opens doors to even broader possibilities. Researchers are already exploring how similar AI models could be adapted to extract biomarkers for other chronic conditions from mammogram images. Potential targets include peripheral artery disease (PAD), a circulatory condition in which narrowed blood vessels reduce blood flow to the limbs, and kidney disease, both of which can have subtle visual indicators that AI might detect. This vision positions the mammogram not merely as a breast cancer screening tool, but as a versatile, opportunistic health screening platform, capable of providing a more comprehensive snapshot of a woman’s overall health status.
The Economic and Societal Impact
The long-term economic and societal impacts of this AI innovation are potentially transformative. By facilitating early detection of cardiovascular risk, the tool could significantly reduce the incidence of costly and debilitating cardiovascular events such as heart attacks and strokes. Early interventions, including lifestyle modifications, preventative medications, and closer medical monitoring, are generally far less expensive than treating acute cardiac emergencies or managing chronic heart failure. This could lead to substantial healthcare cost savings at a national level.
Moreover, the improvement in women’s cardiovascular health would translate into a higher quality of life, increased productivity, and a reduction in premature mortality. It represents a paradigm shift from reactive disease management to proactive preventative care, particularly for a demographic historically underserved in cardiovascular diagnostics. The ability to harness existing, widely-used screening infrastructure for a dual purpose exemplifies efficiency and innovation, setting a new standard for integrated health assessments.
In conclusion, the findings presented at ACC.25 herald a new era in women’s health. By marrying the established practice of mammography with cutting-edge artificial intelligence, healthcare providers gain an unprecedented opportunity to detect not only breast cancer but also critical early indicators of cardiovascular disease. This integrated approach promises to empower women with vital information about their heart health, facilitate earlier interventions, and ultimately save lives, moving us closer to a future where preventative care is truly comprehensive and personalized.
